Mineralys Therapeutics, Inc. MLYS
We take great care to ensure that the data presented and summarized in this overview for Mineralys Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in MLYS
Top Purchases
Top Sells
About MLYS
Insider Transactions at MLYS
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 05
2026
|
David Malcom Rodman Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
192,715
-50.55%
|
$6,745,025
$35.18 P/Share
|
|
Jan 05
2026
|
David Malcom Rodman Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
185,331
+18.12%
|
$2,038,641
$11.39 P/Share
|
|
Jan 02
2026
|
David Malcom Rodman Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
70,037
-50.3%
|
$2,451,295
$35.87 P/Share
|
|
Jan 02
2026
|
David Malcom Rodman Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
67,390
+10.74%
|
$741,290
$11.39 P/Share
|
|
Nov 21
2025
|
Jon Congleton Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
24,082
+3.54%
|
$0
$0.54 P/Share
|
|
Nov 20
2025
|
Brian Taylor Slingsby Director |
SELL
Open market or private sale
|
Indirect |
1,000,000
-11.23%
|
$43,000,000
$43.35 P/Share
|
|
Nov 13
2025
|
Alexander M Gold Director |
SELL
Open market or private sale
|
Direct |
12,742
-100.0%
|
$586,132
$46.5 P/Share
|
|
Nov 13
2025
|
Alexander M Gold Director |
BUY
Exercise of conversion of derivative security
|
Direct |
12,742
+46.99%
|
$140,162
$11.45 P/Share
|
|
Nov 13
2025
|
Daphne Karydas Director |
SELL
Open market or private sale
|
Direct |
15,000
-83.72%
|
$690,000
$46.09 P/Share
|
|
Nov 13
2025
|
Daphne Karydas Director |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+50.0%
|
$150,000
$10.2 P/Share
|
|
Nov 12
2025
|
Alexander M Gold Director |
SELL
Open market or private sale
|
Direct |
6,933
-86.06%
|
$318,918
$46.89 P/Share
|
|
Nov 12
2025
|
Alexander M Gold Director |
BUY
Exercise of conversion of derivative security
|
Direct |
6,933
+50.0%
|
$69,330
$10.2 P/Share
|
|
Nov 11
2025
|
Alexander M Gold Director |
SELL
Open market or private sale
|
Direct |
15,000
-83.33%
|
$660,000
$44.76 P/Share
|
|
Nov 11
2025
|
Alexander M Gold Director |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+50.0%
|
$150,000
$10.2 P/Share
|
|
Nov 11
2025
|
Jon Congleton Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
200,000
-4.36%
|
$8,800,000
$44.23 P/Share
|
|
Nov 11
2025
|
Adam Scott Levy CFO and Secretary |
SELL
Open market or private sale
|
Direct |
119,524
-16.23%
|
$5,139,532
$43.56 P/Share
|
|
Nov 11
2025
|
Adam Scott Levy CFO and Secretary |
BUY
Exercise of conversion of derivative security
|
Direct |
105,653
+21.31%
|
$1,373,489
$13.97 P/Share
|
|
Oct 15
2025
|
David Malcom Rodman Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
10,369
-12.72%
|
$445,867
$43.01 P/Share
|
|
Oct 13
2025
|
Jon Congleton Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
15,100
-0.89%
|
$634,200
$42.83 P/Share
|
|
Oct 13
2025
|
Adam Scott Levy CFO and Secretary |
SELL
Open market or private sale
|
Direct |
10,758
-4.3%
|
$451,836
$42.08 P/Share
|
Last 12 Months Summary
Buy / Acquisition
5.01M
Shares
From
9
Insiders
| Open market or private purchase | 4.52M shares |
|---|---|
| Exercise of conversion of derivative security | 490K shares |
Sell / Disposition
1.95M
Shares
From
6
Insiders
| Open market or private sale | 1.95M shares |
|---|